Liver cancer screening study for people with chronic liver disease
Part of Cancer, Genetic & congenital, Infections, Mouth & dental clinical trials.
This study tests a new way to screen for liver cancer in people with chronic liver disease, especially those with cirrhosis or significant liver scarring. It uses blood tests and imaging to catch cancer early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult with a long-term liver condition like cirrhosis, hepatitis B or C, fatty liver disease, or alcohol-related liver disease, or have significant liver scarring (stage F3).
- You cannot have any active cancer (except common skin cancer that's not melanoma) or a history of liver cancer.
- Your kidneys must be working well enough (your doctor can check a simple blood test).
- You must be willing to have a CT or MRI scan of your liver.
- You must not be pregnant or breastfeeding.
- You should be expected to live at least 2 more years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether offering an ultrasound and a blood test (alpha-fetoprotein) every 6 months can help find liver cancer early in people with cirrhosis (scarred liver) caused by conditions other than hepatitis B or C. The goal is to reduce deaths from liver cancer in this group.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study compares ultrasound scans versus MRI scans to see which one better helps prevent deaths from liver cancer in people with cirrhosis. You may be assigned to one of the two imaging tests and follow-up visits to track whether liver cancer develops or is caught early.
This trial tests a tool to help doctors and patients decide when to screen for liver cancer. It is for people with cirrhosis who have not had imaging in the last 6 months.
This study uses non-invasive tests, like scans or blood tests, to predict how well people with liver cancer (hepatocellular carcinoma, or HCC) will do after curative treatment. It may help doctors better understand your condition without needing invasive procedures.
This study looks at whether adding a blood test (the GAAD score) to standard imaging can better detect liver cancer at an early stage in people with chronic liver disease. It may help you if you have cirrhosis or certain types of liver scarring.
Hear when a new Hepatecellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.